Autolus Therapeutics plc (NASDAQ:AUTL) Sees Significant Growth in Short Interest

Autolus Therapeutics plc (NASDAQ:AUTL) was the target of a significant increase in short interest in the month of June. As of June 15th, there was short interest totalling 6,430,000 shares, an increase of 79.1% from the May 31st total of 3,590,000 shares. Based on an average daily volume of 1,550,000 shares, the short-interest ratio is presently 4.1 days.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Needham & Company LLC reissued a “buy” rating and issued a $9.00 price target on shares of Autolus Therapeutics in a research note on Monday, June 17th. Truist Financial increased their price objective on shares of Autolus Therapeutics from $10.00 to $11.00 and gave the company a “buy” rating in a research report on Tuesday, April 9th. Finally, William Blair restated an “outperform” rating on shares of Autolus Therapeutics in a research report on Monday, June 3rd. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $8.70.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Bayesian Capital Management LP purchased a new stake in Autolus Therapeutics during the first quarter worth approximately $100,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Autolus Therapeutics during the fourth quarter valued at $105,000. B. Riley Wealth Advisors Inc. acquired a new stake in Autolus Therapeutics during the 1st quarter worth about $108,000. SG Americas Securities LLC acquired a new position in Autolus Therapeutics in the first quarter worth approximately $127,000. Finally, EntryPoint Capital LLC grew its holdings in Autolus Therapeutics by 113.6% during the first quarter. EntryPoint Capital LLC now owns 21,540 shares of the company’s stock valued at $137,000 after purchasing an additional 11,456 shares during the last quarter. 72.83% of the stock is owned by hedge funds and other institutional investors.

Autolus Therapeutics Price Performance

Shares of NASDAQ AUTL traded up $0.15 during mid-day trading on Friday, reaching $3.48. The company’s stock had a trading volume of 2,450,789 shares, compared to its average volume of 1,464,718. Autolus Therapeutics has a 1-year low of $2.01 and a 1-year high of $7.45. The stock has a 50-day moving average of $4.03 and a two-hundred day moving average of $5.32.

Autolus Therapeutics (NASDAQ:AUTL) last issued its earnings results on Friday, May 17th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.14). The company had revenue of $10.09 million for the quarter, compared to analysts’ expectations of $50.00 million. During the same quarter last year, the business posted ($0.23) earnings per share. On average, equities analysts predict that Autolus Therapeutics will post -0.78 earnings per share for the current fiscal year.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.